An original investigation published in JAMA Ophthalmology indicated that the megablockbuster metabolic medication Wegovy (semaglutide) may increase the risk of a serious eye condition. The research, published on Wednesday, examined the occurrence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide. The GLP-1 receptor agonists Wegovy, Ozempic, and Rybelsus, all containing the active…